← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 249개
ADCBiologicPfizerPhase 2

Sunitinib Malate (Sunitinib Malate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 59%임상시험 61상태 RECRUITING
CGTBiologicMedigene AGPhase 2

Lymphodepletion (Lymphodepletion)

Epithelial Ovarian Cancer; Gastro-esophageal Junction Cancer · FRα

#FR#CGT#Phase2#인기#세포유전치료+5
효능 0%임상시험 60상태 DISCONTINUED
ADCBiologicSWOG Cancer Research NetworksPhase 3

Afatinib Dimaleate (Afatinib Dimaleate)

Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 96%임상시험 59상태 RECRUITING
ADCBiologicHoffmann-La RochePhase 2

Vismodegib (Vismodegib)

Cancer of Unknown Primary Site · FRα

#FR#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 88%임상시험 59상태 DISCONTINUED
ADCBiologicFavrillederuxtecan for metastatic b…Phase 2

Antibody-Drug Conjugate Therapy (Antibody-Drug Conjugate Therapy)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 86%임상시험 58상태 RECRUITING
ADCBiologicAstraZenecaDM1 in Oatp1a/b -/- was 1Phase 2

Cabazitaxel (Cabazitaxel)

Progressive Metastatic Castrate-Resistant Prostate Cancer · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 57.7%임상시험 57상태 DISCONTINUED
CGTBiologicMarzieh EbrahimiPhase 1

Allogenic NK cells infusion (Allogenic NK cells infusion)

Neuroblastoma, Recurrent, Refractory; Neuroblastoma (NB) · FRα

#FR#CGT#Phase1#인기#세포유전치료+5
효능 ORR 5%임상시험 56상태 RECRUITING
ADCBiologicOHSU Knight Cancer InstituteDM4-6 inhibitors (KDMi), ML…Phase 1

Panobinostat (Panobinostat)

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8 · FRα

#FR#ADC#Phase1#인기#항체약물접합체+5
효능 ORR 80.6%임상시험 55상태 DISCONTINUED
AntibodyPfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 61%임상시험 54상태 RECRUITING
ADCBiologicFondazione per la Medicina Pers…calicheamicin-based antibod…Phase 2

Ponatinib (Ponatinib)

Breast Cancer; Gastrointestinal Cancer · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 7.1%임상시험 54상태 ACTIVE
CGTBiologicKitevedotin plus bendamustine a…Approved

axicabtagene ciloleucel (Yescarta, axi-cel)

Large B-cell Lymphoma; Lymphoma, B-Cell · FRα

#FR#CGT#Approved#인기#세포유전치료+5
효능 ORR 92%임상시험 53상태 RECRUITING
ADCBiologicGilead Sciencesderuxtecan (OR 4Phase 3

Idelalisib (Idelalisib)

Chronic Lymphocytic Leukaemia · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 90.9%임상시험 53상태 DISCONTINUED
ADCBiologicUNICANCERPhase 2

Copanlisib (Copanlisib)

Carcinoma, Squamous Cell of Head and Neck · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 100%임상시험 51상태 DISCONTINUED
AntibodyPfizerPhase 2

PF-06863135 (Elranatamab, Elranatamab (PF-06863135))

Multiple Myeloma · FRα

#FR#Antibody#Phase2#인기#항체+5
효능 ORR 61%임상시험 51상태 ACTIVE
ADCBiologicAstraZenecaderuxtecan or sacituzumab g…Phase 2

Capivasertib (Capivasertib)

Metastatic Breast Cancer · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 56.5%임상시험 50상태 RECRUITING
AntibodyEpizyme, Inc.vedotin in patients with re…Phase 3

Mosunetuzumab (Mosunetuzumab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · FRα

#FR#Antibody#Phase3#항체#면역항체+5
효능 ORR 87.5%임상시험 49상태 RECRUITING
ADCBiologicMedImmune LLCvedotin combined with cispl…Phase 2

DHAP (DHAP)

Diffuse Large B-Cell Lymphoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 47.5%임상시험 48상태 ACTIVE
ADCBiologicPfizerPhase 3

Iberdomide (Iberdomide)

Multiple Myeloma · FRα

#FR#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 92.9%임상시험 47상태 RECRUITING
ADCBiologicPfizerderuxtecan showed encouragi…Phase 1

Dacomitinib (Dacomitinib)

Non-Small Cell Lung Cancer · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 75.3%임상시험 46상태 DISCONTINUED
CGTBiologicHistograft Co., Ltd.operatedPreclinical

"Histograft", a bone substitute based on octacalcium phosphate (OCP, "Histograft", a bone substitute based on octacalcium phosphate, "Histograft", a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene)

Non Union Fracture; Non-Union of Ankle Joint Without Infection · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+5
임상시험 45상태 ACTIVE

2 / 13 페이지

← 이전다음 →